Optimization, validation, and identification of two reliable antibodies for immunodetection of WNT5A

References

• Blast (2015) https://blast.ncbi.nlm.nih.gov/Blast.cgi (accessed September 2015).
   Google Scholar
• Bo H, Zhang S, Gao L, Chen Y, Zhang J, Chang X, Zhu M (2013) Upregulation of Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells. BMC Cancer 13: 496–506.
   PubMed Web of Science ®Google Scholar
• Camilli TC, Weeraratna AT (2010) Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression. Biochem. Pharmacol. 80: 702–711.
   PubMed Web of Science ®Google Scholar
• Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, Hancox RA, Fletcher A, Saldanha GS (2008) WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res. 14: 5825–5832.
   PubMed Web of Science ®Google Scholar
• Dejmek J, Dejmek A, Safholm A, Sjolander A, Andersson T (2005) Wnt-5a protein expression in primary Dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 65: 9142–9146.
   PubMed Web of Science ®Google Scholar
• Diaz Prado SM, Medina Villaamil V, Aparicio Gallego G, Blanco Calvo M, Lopez Cedrun JL, Sironvalle Soliva S, Valladares Ayerbes M, Garcia Campelo R, Anton Aparicio LM (2009) Expression of Wnt gene family and frizzled receptors in head and neck squamous cell carcinomas. Virchows Arch. 455: 67–75.
   PubMed Web of Science ®Google Scholar
• Fracalossi AC, Silva Mde S, Oshima CT, Ribeiro DA (2010) Wnt/beta-catenin signalling pathway following rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. Exp. Mol. Pathol. 88: 176–183.
   PubMed Web of Science ®Google Scholar
• Gremel G, Bergman J, Djureinovic D, Edqvist PH, Maindad V, Bharambe BM, Khan WA, Navani S, Elebro J, Jirstrom K, Hellberg D, Uhlen M, Micke P, Ponten F (2014) A systematic analysis of commonly used antibodies in cancer diagnostics. Histopathology 64: 293–305.
   PubMed Web of Science ®Google Scholar
• Hewitt SM, Baskin DG, Frevert CW, Stahl WL, Rosa-Molinar E (2014) Controls for immunohistochemistry: the Histochemical Society’s standards of practice for validation of immunohistochemical assays. J. Histochem. Cytochem. 62: 693–697.
   PubMed Web of Science ®Google Scholar
• Holmseth S, Zhou Y, Follin-Arbelet VV, Lehre KP, Bergles DE, Danbolt NC (2012) Specificity controls for immunocytochemistry: the antigen preadsorption test can lead to inaccurate assessment of antibody specificity. J. Histochem. Cytochem. 60: 174–187.
   PubMed Web of Science ®Google Scholar
• Jenei V, Sherwood V, Howlin J, Linnskog R, Safholm A, Axelsson L, Andersson T (2009) A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc. Natl. Acad. Sci. USA 106: 19473–19478.
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Yamamoto H, Sato A, Matsumoto S (2012) Wnt5a: its signalling, functions and implication in diseases. Acta Physiol. 204: 17–33.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park S, Chung H, Oh S (2015) Wnt5a attenuates the pathogenic effects of the Wnt/beta-catenin pathway in human retinal pigment epithelial cells via down-regulating beta-catenin and Snail. Biochem. Mol. Biol. Rep. 48: 525–530
   Google Scholar
• Kremenevskaja N, von Wasielewski R, Rao AS, Schofl C, Andersson T, Brabant G (2005) Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144–2154.
   PubMed Web of Science ®Google Scholar
• Kurayoshi M, Yamamoto H, Izumi S, Kikuchi A (2007) Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochem. J. 402: 515–523.
   PubMed Web of Science ®Google Scholar
• Li J, Ying J, Fan Y, Wu L, Ying Y, Chan AT, Srivastava G, Tao Q (2010) WNT5A antagonizes WNT/beta-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer. Biol. Ther. 10: 617–624.
   PubMed Web of Science ®Google Scholar
• Li P, Cao Y, Li Y, Zhou L, Liu X, Geng M (2014) Expression of Wnt-5a and beta-catenin in primary hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 7: 3190–3195.
   PubMed Web of Science ®Google Scholar
• Liu XH, Pan MH, Lu ZF, Wu B, Rao Q, Zhou ZY, Zhou XJ (2008) Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma. Dig. Liver Dis. 40: 560–567.
   PubMedGoogle Scholar
• Nishita M, Enomoto M, Yamagata K, Minami Y (2010) Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol. 20: 346–354.
   PubMed Web of Science ®Google Scholar
• O’Hurley G, Sjostedt E, Rahman A, Li B, Kampf C, Ponten F, Gallagher WM, Lindskog C (2014) Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol. Oncol. 8: 783–798.
   PubMed Web of Science ®Google Scholar
• Prasad CP, Chaurasiya SK, Axelsson L, Andersson T (2013) WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol. Oncol. 7: 870–883.
   PubMed Web of Science ®Google Scholar
• Prgomet Z, Axelsson L, Lindberg P, Andersson T (2015) Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression. J. Oral Pathol. Med. 44: 776–784.
   PubMed Web of Science ®Google Scholar
• Ring L, Neth P, Weber C, Steffens S, Faussner A (2014) Beta-catenin-dependent pathway activation by both promiscuous “canonical” WNT3a-, and specific “noncanonical” WNT4- and WNT5a-FZD receptor combinations with strong differences in LRP5 and LRP6 dependency. Cell. Signaling 26: 260–267.
   PubMed Web of Science ®Google Scholar
• Roarty K, Baxley SE, Crowley MR, Frost AR, Serra R (2009) Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res. 11: R19.
   PubMed Web of Science ®Google Scholar
• Saitoh T, Mine T, Katoh M (2002) Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int. J. Mol. Med. 9: 515–519.
   PubMed Web of Science ®Google Scholar
• Sand-Dejmek J, Ehrnstrom R, Berglund P, Andersson T, Ryden L (2013) The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women. PLoS One 8: e70890.
   PubMed Web of Science ®Google Scholar
• Schuster C, Malinowsky K, Liebmann S, Berg D, Wolff C, Tran K, Schott C, Reu S, Neumann J, Faber C, Hofler H, Kirchner T, Becker KF, Hlubek F (2012) Antibody validation by combining immunohistochemistry and protein extraction from formalin-fixed paraffin-embedded tissues. Histopathology 60: E37–50.
   PubMed Web of Science ®Google Scholar
• Syed Khaja AS, Helczynski L, Edsjo A, Ehrnstrom R, Lindgren A, Ulmert D, Andersson T, Bjartell A (2011) Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One 6: e26539.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Matsubara S, Kuwata T, Saruyama M, Usui R, Ohkuchi A, Takizawa T, Suzuki M (2014) Changes in expression of vascular endothelial growth factor D-related genes in placental mesenchymal dysplasia. J. Obstet. Gynaecol. Res. 40: 1145–1149.
   PubMed Web of Science ®Google Scholar
• Voskuil J (2014) Commercial antibodies and their validation. F1000 Res 3: 232.
   PubMedGoogle Scholar
• Wieczorek R, Stover R, Sebenik M (1997) Nonspecific nuclear immunoreactivity after antigen retrieval using acidic and basic solutions. J. Histotechnol. 20: 139–143.
   Web of Science ®Google Scholar
• Zhong Z, Shan M, Wang J, Liu T, Shi Q, Pang D (2016) Decreased Wnt5a expression is a poor prognostic factor in triple-negative breast cancer. Med. Sci. Monit. 22: 1–7.
   PubMed Web of Science ®Google Scholar